Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Top Headlines

Orchard to build $80m gene therapy manufacturing facility

Orchard signed a long-term lease agreement to build-out an $80m gene therapy manufacturing facility in Fremont, California.

European biotech an attractive option for Chinese investment, says VC exec

Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.

Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency

Scope’s report finds biologics likely to be protected from severe biosimilar erosion but sees warning signs for the generics industry.

Insulin biosimilars? US FDA readies market for entry

From March 2020, insulin medication will be regulated as a biologic drug, allowing biosimilar competition in a ‘watershed moment’.

Chinese firm plans ‘first-in-class’ biologics after $325m manufacturing investment

The second phase of Changzhou Qianhong Bio-pharma manufacturing project sees a further ¥1 billion devoted to increasing tablet and injection production.